Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 558 followers
Latest posts
Last updated about 2 hours ago
GSK’s Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression
about 1 hour ago
Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) is the first and only...
Luke Miels appointed CEO designate for GSK
15 days ago
Luke to assume full responsibilities as CEO from 1st January 2026
GSK to submit label update for Wellcovorin (leucovorin) at US FDA’s request
22 days ago
GSK confirmed today that it will submit a supplemental New Drug Application...
GSK to invest $30 billion in R&D and Manufacturing in the United States over next 5 years
27 days ago
New facilities will bridge R&D and manufacturing across both the US and...
GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society (ERS) Congress 2025
29 days ago
60+ abstracts highlight GSK ambition in respiratory diseases to reduce exacerbations, prevent...
Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhoea
2 months ago
Submission supported by positive phase III data in patients with uncomplicated urogenital...
GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation
2 months ago
CureVac will make an upfront settlement of $370 million to GSK
GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation
3 months ago
Real-world data shows an association between Recombinant Zoster Vaccine (RZV) and potential...
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
3 months ago
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for...
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma
3 months ago
Sixth regulatory approval for Blenrep combinations with applications under review in all...
GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma
3 months ago
New PDUFA date scheduled for 23 October 2025.